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AdolescentsBackground: Human Papillomavirus (HPV) causes significant burden of HPV-related diseases, which are
more prevalent in immunosuppressed compared to immunocompetent people. We conducted a multi-
centre clinical trial to determine the immunogenicity and reactogenicity of HPV vaccine in immunocom-
promised children. Here we present the immunogenicity results 5 years post vaccination.
Methods: We followed up immunocompromised children (5–18 years) with a range of specified underly-
ing conditions who were previously recruited from three Australian paediatric hospitals. Participants
received three doses of quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11, 16, 18) and
were followed up between 2007 and 2016 (60 months post-vaccination). The immunogenicity primary
outcome was seroconversion and geometric mean titres (GMT) of the quadrivalent HPV vaccine serotypes
in the study.
Results: Of the 59 original participants, 37 were followed up at 60 months. The proportion of participants
who seroconverted were: 86.5%, 89.2%, 89.2%, 91.9% by competitive Luminex immunoassay (cLIA) and
83.8%, 83.8%, 94.6%, 78.4% by total immunoglobulin G assays (IgG) for serotypes 6, 11, 16 and 18 respec-
tively. GMT values ranged from 118 (95%CI: 79–177) for serotype 11, to 373 (95%CI: 215–649) for sero-
type 16 by cLIA. For IgG, serotype 16 had the highest GMT of 261 (95%CI: 143–477) and serotype 18 had
the lowest value of 37 (95%CI: 21–68). All antibody titres were lower in females compared to males but
the difference was not statistically significant except for serotype 16. No serious adverse event was
reported during this follow-up period.
Conclusion: Our evidence, although limited by small numbers, is reassuring that a three dose schedule of
HPV vaccine remains immunogenic in immunocompromised children to five years post vaccination.
Large scale studies are required to determine long term protection in immunocompromised children.
Clinical trial registration: NCT02263703 (ClinicalTrials.gov).
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
Human Papillomavirus (HPV) causes significant burden of HPV-
related diseases, which are more prevalent in immunosuppressedchildren compared to immunocompetent children [1–7]. Vaccina-
tion is an effective measure to protect against HPV infection and
HPV-related disease and has the potential to reduce HPV disease
incidence in immunocompromised patients [8–12]. Based on the
2017 World Health Organisation (WHO) position paper on HPV
vaccines, a three-dose schedule (0, 1–2, 6 months) of either biva-
lent, quadrivalent and nonavalent vaccines is recommended for
individuals who are immunocompromised, or over 15 years of
age [13].
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ness of the vaccine, as the potential risk of HPV exposure remains
present throughout an individual’s lifetime. Several studies have
investigated long-term immunogenicity of HPV vaccine. Einstein
et al. [14] compared immunogenicity among healthy women aged
18–45 years up to 60 months post vaccination with bivalent or
quadrivalent vaccines and found adequate seroconversion rates
for HPV-16. However, for HPV-18, whilst there were high seropos-
itivity rates among the bivalent vaccine group (98.1%–100%),
decreasing seropositivity rates were reported among the quadriva-
lent vaccine group (61.1%–76.9%). A randomised, partially blind
study evaluated the immunogenicity of bivalent HPV vaccine given
in two doses to girls 9–14 years of age and in three doses to women
15–25 years of age. All participants who were seronegative at base-
line were seropositive for anti-HPV16 and 18 after five years, and
statistical models predicted that antibody levels would remain
higher than natural-infection levels for at least 21 years in 95% of
subjects [15]. A long-term follow up study measuring the immuno-
genicity of bivalent HPV vaccine in women aged 15–55 found that
ten years after vaccination, seropositivity to anti-HPV-16 among
women aged 15–25 years was 100% and to anti-HPV-18 was
99.2%. Immunity was predicted to remain above natural infection
levels for at least 30 years [16].
In a double-blind, randomized, placebo-controlled study evalu-
ating the long-term efficacy of bivalent HPV vaccine among young
women aged 15–25 years, vaccine efficacy was found to remain
high (95.6%) at 9.4 years [17]. A double-blind, placebo-controlled
study evaluating the immunogenicity of quadrivalent HPV vaccine
among 9- to 15-year-old boys and girls found no persistent infec-
tions among the participants 8 years post vaccination [18].
The immunogenicity of HPV vaccine among immunosuppressed
paediatric populations has been evaluated in a handful of studies,
however few studies investigated long-term (>2 years) persistence
of immunogenicity [19–24]. Weinberg et al [25] measured
antibody levels of 97 HIV-positive children four to five years
after receiving three or four doses of quadrivalent HPV vaccine in
a double-blind, placebo-controlled study. This study found that
T-cell responses to HPV-16 and -18 persisted over the follow up
period for both study groups, but there were notable decreases
in B-cell responses and T-cell function [25].
Our previous study, a multicentre clinical trial in Sydney and
Adelaide, Australia showed a robust immune response in immuno-
compromised children after 7 and 24 months post vaccination
with quadrivalent HPV vaccines [24]. The seroconversion rates
were 93.3%, 100%, 100% and 88.9% for serotypes 6, 11, 16 and 18
respectively. The corresponding rates at 24 months follow up were
82.2%, 91.1%, 91.1% and 68.9% [24]. The present study evaluated
the long-term persistence of immunogenicity by means of serocon-
version and geometric mean titres (GMT) in participants at 5 years
post vaccination with the quadrivalent HPV vaccine.2. Methods
2.1. Participants and study design
The patient characteristics, eligibility criteria, study methods,
and 7- and 24-month results of the clinical trial have previously
been published [24]. A prospective, multicentre clinical trial was
conducted between November 2007 and October 2012 at three
paediatric hospitals in Sydney and Adelaide, Australia to determine
the immunogenicity and reactogenicity of HPV vaccine in
immunocompromised children. Participants included unvacci-
nated patients aged between 5 and 18 years, diagnosed with either
solid organ transplantation (liver (LT) or kidney (KT)), haematolog-
ical stem cell transplantation (HSCT), or an autoimmune disorder(Juvenile Idiopathic Arthritis (JIA) or inflammatory bowel disease,
IBD). A total of 59 participants were enrolled (13 LT, 16 KT, 20
HSCT, 7 JIA and 3 IBD).
As reported previously, participants were given three doses of
quadrivalent HPV vaccine (Gardasil Quadrivalent HPV Types 6, 11,
16, 18). Participants were followed for up to 5-years post vaccina-
tion. Serum samples for serologic analysis were collected at base-
line (before first dose), 7, 24 and 60 months. Serum antibody
levels to serotypes 6, 11, 16 and 18 were quantified by a IgG
Luminex immunoassay [26–28] and a Luminex immunoassay in a
competitive format (cLIA), in which type-specific, phycoerythrin-
labelled, neutralising antibodies compete with patient serum
antibodies for binding to conformationally sensitive, neutralising
epitopes on the VLPs [24,26,29,30]. Additional details on serum
collection and assay methods have been published previously
[24]. Serologic analysis was conducted by Merck Laboratories.
Seroconversion and geometric mean titres (GMT) for serotypes
6, 11, 16 and 18 were calculated for each serotype at respective time
points. Titres were compared over time for each serotype and
between different groups (age, gender and use of immunosuppressive
drugs) using students t-testwith lognormal distribution. Herewe pre-
sent the analysis at month 60, as well as the analysis at months 7 and
24 among the participants that completed the five year follow up.
2.2. Ethics approval and consent
Ethics approval was obtained from the Human Research Ethics
Committee (HREC) of the SESLHD/Northern Hospital Network (no –
07/280), Children, Youth and Women’s Health Service (CYWHS)
Research Ethics Committee (no – REC2016/12/10) and the Chil-
dren’s Hospital at Westmead Ethics committee (no  2007/028).
This trial was registered at ClinicalTrials.gov (identifier:
NCT02263703). Informed consent was obtained from the parent
of the participants prior to vaccination.3. Results
3.1. Characteristics of study participants
Of the 59 original participants, 37 were followed up at
60 months (Fig. 1). Of these 37 participants, 34 were successfully
followed up at 7 and 24 months. Patient characteristics are sum-
marized in Table 1. Participant age at the 60 months follow up ran-
ged from 10 years to 23 years, with a mean and median of
17.0 years. Nineteen (51.4%) were female, and 18 (48.6%) were
male. Most participants (64.9%) in the follow up study were
enrolled from Hospital 1. Fifteen (40.5%) participants had under-
gone HSCT at the time of recruitment, and 14 (37.8%) underwent
a solid organ transplant at the time of recruitment. Six participants
(16.2%) were on one immunosuppressive agent at the time of
recruitment, and 14 participants (37.8%) were on more than one
immunosuppressive agent. The remaining participants were not
on an immunosuppressive agent at baseline (n = 16, 43.2%) or the
data were missing (n = 1, 2.7%).
Participants in the follow up study did not differ significantly
from the full study population in terms of age, gender, underlying
condition, or use of immunosuppressive agents. However, hospital
of origin did differ significantly between the follow up group and
the full study population, as a much greater proportion of patients
were followed up from hospital 1 compared to hospitals 2 and 3.
3.2. Immunogenicity
The proportion of participants who seroconverted were: 86.5%,
89.2%, 89.2%, 91.9% by competitive Luminex immunoassay (cLIA)
Total parcipants - 59
Hospital 1 - 32
Hospital 2 - 11
Hospital 3 - 16
Cases 
enrolled
HSCT1 - 20
Cases 
enrolled
LT2 13
Cases 
enrolled
KT3 - 16
Cases 
enrolled
IBD4 - 3
Cases 
enrolled
JIA5 - 7
Dose 16 - 20
Dose 2 - 19
Dose 3 - 18
Dose 1 - 11
Dose 2 - 10
Dose 3 - 9
Dose 1 - 16
Dose 2 - 16
Dose 3 - 16
Dose 1 - 3
Dose 2 - 3
Dose 3 - 3
Dose 1 - 7
Dose 2 - 7
Dose 3 - 6
Test 17 - 20
Test 2 - 18
Test 3 - 17
Test 4 - 15
Test 1 - 9
Test 2 - 9
Test 3 - 9
Test 4 - 8
Test 1 - 15
Test 2 - 9
Test 3 - 10
Test 4 - 6
Test 1 - 3
Test 2 - 3
Test 3 - 3
Test 4 - 3
Test 1 - 6
Test 2 - 6
Test 3 - 6
Test 4 - 5
1Haematological stem cell transplantaon 
2Liver transplant 
3Kidney transplant  
4Inflammatory bowel disease 
5Juvenile idiopathic arthris 
6Indicates number of subjects that received each of three doses of quadrivalent HPV vaccine (Dose 1, 
Dose 2, Dose 3) 
7Indicates number of subjects that had serum samples tested for anbody tres at each of four me 
points (Test 1 = baseline pre-vaccinaon, Test 2= 7 months post-vaccinaon, Test 3 = 24 months 
post-vaccinaon, Test 4 = 60 months post-vaccinaon) 
Fig. 1. Recruitment. 1Haematological stem cell transplantation. 2Liver transplant. 3Kidney transplant. 4Inflammatory bowel disease. 5Juvenile idiopathic arthritis. 6Indicates
number of subjects that received each of three doses of quadrivalent HPV vaccine (Dose 1, Dose 2, Dose 3). 7Indicates number of subjects that had serum samples tested for
antibody titres at each of four time points (Test 1 = baseline pre-vaccination, Test 2 = 7 months post-vaccination, Test 3 = 24 months post-vaccination, Test 4 = 60 months
post-vaccination).
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(IgG) for serotypes 6, 11, 16 and 18 respectively. GMT values
obtained by cLIA at 60 months, ranged from 118 (95%CI: 79–177)
for serotype 11, to 373 (95% CI: 215–649) for serotype 16. GMTs
were higher at 60 months, compared to baseline. GMTs of sero-
types 6 and 18 were higher at 60 months compared to 24 months,
but the difference was not significant. Serotype 16 had the highest
IgG GMT of 261 (95%CI: 143–477) and serotype 18 had the lowest
value of 37 (95%CI: 21–68) (Table 2).
All antibody titres were lower in females compared to males at
60 months, but the difference was not statistically significantexcept for serotype 16. Antibody titers at 60 months were not sig-
nificantly different between <12 and 12 years age groups nor
between patients taking immunosuppressive drugs or not (Table 3).
No serious adverse event was reported during this follow up
period.
GMT values did not differ significantly between those that com-
pleted the follow up and those that did not for any time point or
serotype. Results obtained from the follow up sample did not differ
from the full sample, except when comparing GMT’s by age. GMT’s
were lower among the older age group compared to the younger
age group for all serotypes at all timepoints, but this difference
Table 1
Patient characteristics at 60 months follow up (n = 37).
Variable Number (%)
Age
Mean (range) 17.0 (10–23)
Gender
Female 19 (51.4)
Male 18 (48.6)
Hospital of origin
Hospital 1 24 (64.9)
Hospital 2 7 (18.9)
Hospital 3 6 (16.2)
Underlying condition
Haematological stem cell transplantation (HSCT) 15 (40.5)
Liver transplantation 8 (21.6)
Kidney transplantation 6 (16.2)
Juvenile Idiopathic Arthritis 5 (13.5)
Inflammatory bowel disease 3 (8.1)
Immunosuppression at baseline
No immunosuppressive agents 16 (43.2)
One immunosuppressive agent 6 (16.2)
More than one immunosuppressive agent 14 (37.8)
Missing data 1 (2.7)
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low up sample, the difference was significant for serotype 11 at
24 months.4. Discussion
This follow-up study examined long-term immunogenicity of
HPV vaccine among immunocompromised children. In this hetero-
geneous group of immunosuppressed children, there was an ade-
quate immunogenic response to HPV vaccine irrespective of age
or the cause of immunosuppression. The HPV vaccine was found
to be immunogenic and all antibody titres remained higher than
baseline at the end of 5 years follow-up in immunocompromised
children 60 months after completion of a 3-dose schedule.
Although antibody titers are the most common endpoints in HPV
vaccine studies, it is important to note that there are no clearly
defined correlates of protection against HPV-related outcomes
[31].
Although the proportion of seroconverted children at 5 years
post HPV vaccination was lower than 7 months post-vaccination,Table 2
Proportion of seroconversion and Geometric mean titres (GMT) at three time points.
Seroconversion
Serotype Baseline cLIA* %
(seropositive/total)
7 months cLIA* %
(seropositive/total)
24 months cLIA* %
(seropositive/total)
6 0% (0/36) 91.2% (31/34) 88.2% (30/34)
11 0% (0/36) 100% (34/34) 94.1% (32/34)
16 0% (0/36) 100% (34/34) 94.1% (32/34)
18 0% (0/36) 91.2% (31/34) 79.4% (27/34)
Geometric mean titres (GMT)
Serotype Baseline cLIA*GMT (CI)

7 months cLIA*GMT
(CI) 
24 months cLIA*GMT
(CI) 
6 11.2 (10.8–11.5) 458.2 (263–797) 137 (89–210)
11 8.0 (8.0–8.0) 833 (525–1322) 156 (101–240)
16 11 (11.0–11.0) 3122 (1780–5476) 543 (316–932)
18 10.0 (10.0–10.0) 548 (290–1033) 88 (52–150)
* cLIA – competitive Luminex immunoassay.
y IgG – Total immunoglobulin G assays.
 GMT in milli-Merck units (mMU) per millilitre and 95% confidence interval.immunity was higher for serotypes 6 and 18 compared to
24 months. Among the four serotypes present in the vaccine, sero-
types 16 and 18 are associated with cervical cancer. The majority
(7/8) of participants lost to follow up between 24 months and
5 years were seronegative for serotype 18 at 24 months, and half
(4/8) were seronegative for serotype 6 at 24 months. Therefore,
immunity at 5 years for these two serotypes may be biased
towards higher results in the study participants who completed
the 5 years follow-up. Increasing GMTs could also reflect natural
exposure or undocumented re-vaccination. Increased exposure to
HPV in the children is likely, given many were in their late teens
or older at 60 months of follow up. Vaccination is provided as a
school-based program in high school in Australia, so it is possible
some children were revaccinated although this question was asked
at follow-up study visits. Ferris et al reported higher GMTs for all
serotypes in their follow-up study of immunocompetent patients,
and showed GMTs for serotype 6, 11, 16 and 18 were higher at
72 months compared to 60 months [18].
Antibody response to serotype 11 and 16 were reduced at
60 months in our study, compared to 24 months, although not sig-
nificantly. This is a potential concern as serotype 16 is the most
common cause of cervical cancer [32]. Einstein et al reported a
reduction in GMTs for serotypes 16 and 18 over time in immuno-
competent patients. In their study GMTs peaked at 7 months post-
vaccination and declined to a plateau at 18–24 months through to
60 months [14]. Plateau antibody levels of serotype 16 and 18
induced by the quadrivalent vaccine and bivalent vaccine were
above the levels induced by natural infection, although plateau
levels induced by the bivalent vaccine were higher than that of
the quadrivalent vaccine [14]. Naud, Roteli-Martins [17] similarly
reported a decline in serotype 16 and 18 IgG antibodies over time
in immunocompetent subjects. Whilst all vaccinated study partic-
ipants remained seropositive to serotypes 16 and 18 up to
113 months post-vaccination, plateaus were reached at approxi-
mately 18 months after the first vaccine dose [17].
Ferris et al conducted a long-term study of quadrivalent HPV
vaccine administered at 0, 2, and 6 months in healthy children
and adolescents similar in age to our study [18,33]. A plateau effect
was observed in this study as well, which persisted throughout the
ten year follow up [33]. Interestingly, the GMT levels at month 60
were lower for all four serotypes compared to our study. Thus,
although GMT levels decreased slightly between 24 and 60 months
in our study, they may remain fairly stable over time.
The GMT levels obtained through the cLIA were higher com-
pared to the IgG assays, although the clinical significance of this60 months cLIA* %
(seropositive/total)
24 months IgGy %
(seropositive/total)
60 months IgGy %
(seropositive/total)
86.5% (32/37) 97.3% (36/37) 83.8% (31/37)
89.2% (33/37) 100% (37/37) 83.8% (31/37)
89.2% (33/37) 97.3% (36/37) 94.6% (35/37)
91.9% (34/37) 100% (37/37) 78.4% (29/37)
60 months cLIA*GMT
(CI) 
24 months IgGy GMT
(CI) 
60 months IgGy GMT
(CI) 
149 (102–219) 117 (69–199) 60 (35–102)
118 (79–177) 97 (59–161) 45 (27–75)
373 (215–649) 532 (301–938) 261 (143–477)
141 (100–198) 88 (52–150) 37 (21–68)
Table 3
Geometric mean titres (competitive Luminex immunoassay) by gender, age and use of immunosuppressive drugs.
Antibody type Month* GMT (mMU per ml)
95% confidence interval
GMT ratio (mMU per ml) 95% CI
Gender Male Female
6 7 868 (523–1440) 242 (94–620) 3.59 (1.29–10.02)
24 203 (134–308) 92 (43–196) 2.21 (0.97–5.05)
60 191 (118–307) 118 (63–220) 1.61 (0.75–3.46)
11 7 1355 (903–2033) 513 (228–1153) 2.64 (1.11–6.31)
24 225 (134–379) 107 (53–218) 2.10 (0.90–4.89)
60 144 (84–247) 98 (53–184) 1.46 (0.65–3.26)
16 7 6125 (4000–9378) 1591 (592–4277) 3.84 (1.37–10.83)
24 1083 (607–1932) 272 (118–630) 3.98 (1.49–10.60)
60 695 (347–1389) 208 (91–472) 3.35 (1.18–9.51)
18 7 1064 (558–2026) 282 (97–820) 3.77 (1.14–12.49)
24 150 (81–282) 51 (22–119) 2.93 (1.07–8.02)
60 169 (103–277) 118 (71–197) 1.43 (0.72–2.85)
Age <12 years 12 years
6 7 740 (308–1782) 314 (151–653) 2.36 (0.79–7.02)
24 217 (115–410) 95 (53–170) 2.28 (0.99–5.22)
60 191 (101–361) 121 (74–198) 1.58 (0.73–3.39)
11 7 1020 (479–2172) 711 (379–1332) 1.43 (0.56–3.66)
24 270 (161–453) 101 (53–190) 2.68 (1.18–6.07)
60 161 (90–289) 91 (51–161) 2.12 (0.80–3.92)
16 7 3467 (1354–8878) 2874 (1342–6155) 1.20 (0.38–3.81)
24 770 (408–1453) 412 (174–974) 1.87 (0.63–5.53)
60 527 (240–1159) 279 (123–630) 1.89 (0.63–5.72)
18 7 625 (246–1586) 494 (192–1268) 1.26 (0.35–4.62)
24 114 (53–245) 72 (33–157) 1.58 (0.54–4.61)
60 158 (97–257) 128 (76–214) 1.24 (0.62–2.48)
Immunosuppressive drugs Yes No
6 7 380 (142–1019) 582 (304–1114) 1.53 (0.49–4.83)
24 126 (64–250) 141 (75–264) 1.12 (0.46–2.74)
60 154 (88–270) 136 (74–251) 0.88 (0.40–1.96)
11 7 561 (245–1284) 1158 (755–1776) 2.06 (0.83–5.14)
24 143 (69–297) 157 (89–279) 1.10 (0.45–2.71)
60 137 (77–241) 93 (49–177) 0.68 (0.30–1.55)
16 7 2016 (712–5711) 4569 (2804–7446) 2.26 (0.73–7.00)
24 425 (177–1019) 647 (306–1367) 1.52 (0.50–4.62)
60 369 (170–803) 347 (138–868) 0.94 (0.30–2.97)
18 7 310 (102–943) 847 (469–1532) 2.73 (0.80–9.36)
24 69 (32–147) 98 (44–219) 1.43 (0.50–4.11)
60 133 (82–216) 135 (80–226) 1.02 (0.51–2.02)
24 month titre levels were available for 34 participants – Male (17), female (17), <12 years (15) and  12 years (19), Participants on immunosuppressive drugs (17), no drugs
(16), missing data (1).
60 month titre levels were available for 37 participants – Male (18), female (19), <12 years (17) and  12 years (20), Participants on immunosuppressive drugs (20), no drugs
(16), missing data (1).
* 7 month titre levels were available for 34 participants – Male (17), female (17), <12 years (15) and  12 years (19), Participants on immunosuppressive drugs (17), no
drugs (16), missing data (1).
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greater number of seronegative than seropositive participants
being lost to follow up between 24 and 60 months. However, even
when restricting results to just participants that were followed up
at all time points, GMT for serotype 18 still increased between 24
and 60 months. Our results at each time point did not differ signif-
icantly when compared between the full sample and the smaller
follow up sample, suggesting that our follow up sample is repre-
sentative of the full study group and little to no selection bias
occurred at 60 months.
Females, older children and those on immunosuppressive drugs
had lower responses to the vaccine. Similarly, Einstein et al
reported a significantly higher number of participants in younger
age groups remained seropositive for serotype 18 antibodies com-
pared with the older age groups [14]. Other studies found similar
gender differences. In boys, post vaccination antibody levels for
both serotype 16 and 18 were observed to be up to threefold
higher compared to women and girls [34–36]. Differences in
immune responses to vaccinations between males and females
have been well documented, though the specific mechanisms for
this are not fully understood [37–40]. Vaccine responses arethought to be modulated by sex-differential factors such as sex
hormones and sex-linked immune response genes [39,40].
Limitations of this study include the small sample size and a
heterogeneous patient group ranging from bone marrow and solid
organ transplant to autoimmune diseases. We did not have ade-
quate statistical power to compare different patient groups. We
had a significantly greater proportion of patients lost to follow
up from hospitals 2 and 3 compared to hospital 1, which could
have resulted in some selection bias if the three hospitals served
significantly different populations. While we did not observe any
differences in GMT levels at 7 and 24 months between those that
were followed up at 60 months and those that were lost to follow
up, we may have lacked sufficient statistical power to detect these
differences. Further, at the time of the study, Australia recom-
mended a 3-dose schedule for quadrivalent HPV vaccine. This
was replaced by a 2-dose schedule of 9-valent HPV vaccine for chil-
dren 9–14 years in 2018 [41–45] with a three dose schedule still
recommended for medically at risk children.
Whilst this study provides immunological evidence of persist-
ing immunity, further studies are needed to determine long term
clinical protection in immunocompromised children.
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